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Blockade of dopamine D1 receptors in male rats 
disrupts morphine reward in pain naïve but not in 
chronic pain states





























drug	 naïve	 and	 drug‐dependent	 states.	Neuroadaptations	 associated	with	 chronic	






















Johannes,	 Le,	 Zhou,	 Johnston,	 &	 Dworkin,	 2010;	 Schopflocher,	
Taenzer,	&	 Jovey,	2011),	 is	 commonly	 treated	with	opioid	analge-
sics.	Although	effective	 in	 the	short‐term,	 long‐term	use	of	 these	
drugs	 can	 lead	 to	 reduced	 analgesia	 (tolerance)	 (Christie,	 2008),	
hyperalgesia	(Mao,	2002),	and	addiction	(Contet,	Kieffer,	&	Befort,	
2004).	Diversion	 of	 prescription	 opioids	 exacerbates	 these	 prob-
lems	and	has	contributed	to	an	epidemic	of	drug	overdose	and	death	
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treatments	 for	 chronic	 pain	 with	 low	 abuse	 potential	 (Evans	 &	
Cahill,	2016).
A	major	challenge	in	this	endeavor	is	that	chronic	pain,	itself,	al-
ters	 brain	 reward	 systems	 (Taylor,	 Becker,	 Schweinhardt,	 &	 Cahill,	
2016;	Trang	et	al.,	2015)	that	are	associated	with	addiction	(Volkow,	
Koob,	&	McLellan,	2016;	Wise,	2008).	For	example,	induction	of	neu-


























intensity	 across	 an	 8	 to	 12‐day	 period	 in	 rats.	 A	 time‐dependent	
change	 in	 sensory	 hypersensitivities	 reflect	 neuroadaptations	 fol-
lowing	nerve	injury,	with	distinct	biological	processes	mediating	pain	










2  | MATERIAL S AND METHODS
2.1 | Subjects
Three	hundred	and	three	male	Sprague‐Dawley	rats,	weighing	250–





NY)	 and	 a	 black,	 plastic	 tube	 (PVC	 piping	 ~7.5	 cm	 diameter)	 pro-
vided	as	enrichment.	Cages	were	kept	in	a	climate‐controlled	room	
(21°C)	on	a	reverse	12:12	hr	light	cycle	(lights	off	at	07:00	hr),	with	
humidity	 levels	 ranging	 from	20%	to	70%	across	seasons.	Animals	
had	ad libitum	access	to	standard	rat	chow	(Labdiet,	PMI	Nutrition	










The	 CPP	 apparatus	 was	 made	 of	 plexiglass	 and	 consisted	 of	 two	






ment.	 Cameras	were	mounted	 directly	 above	 each	 set	 of	 boxes	 so	







Rats	 were	 randomly	 assigned	 to	 neuropathic	 or	 sham	 surgery	
groups;	neuropathic	pain	was	induced	through	CCI	of	the	sciatic	
Significance






alterations	 to	 reward	 system	 function	 in	 chronic	 pain.	 Our	
study	 is	 timely	 given	 the	 current	 opioid	 epidemic	 and	 the	
pressing	 need	 to	 develop	 new	 therapeutic	 compounds	 for	
chronic	pain	with	minimal	abuse	potential.
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nerve	 (Bennett	&	Xie,	 1988).	 Prior	 to	 surgery,	 animals	 received	
liquid	acetaminophen	 (0.6	ml	of	32	mg/L	dose,	orally)	and	were	
then	 anesthetised	 under	 isoflurane	 (5	 L/min	 induction,	 2–3	 L/
min	maintenance).	All	animals	received	5	ml	of	Lactated	Ringer's	
Solution	by	subcutaneous	 (s.c.)	 injection.	The	 left	hind	 limb	was	
shaved	 and	 cleaned	with	 alcohol	 and	 Betadine	 solution.	 An	 in-
cision	 was	 made	 on	 the	 hind	 limb	 and	 the	 muscle	 layers	 were	
bluntly	dissected	with	scissors	to	expose	the	sciatic	nerve.	Using	










nist),	 and	eticlopride	 (DA	D2	 receptor	antagonist)	were	purchased	




2.5.1 | Establishing a morphine CPP in early and late 
phases of chronic pain
Separate	 groups	 of	CCI	 rats	were	 tested	 for	 a	morphine	CPP	 in	
early	 (n	=	8)	and	 late	phases	 (n	=	10)	of	chronic	pain	to	establish	
doses	 that	produced	a	CPP	 in	each	condition	 (post‐surgery	days	










The	 lowest	 dose	 tested	 (2	 mg/kg)	 produced	 a	 CPP	 in	 a	 late	
[t(9)	=	8.413,	p	<	0.001],	but	not	an	early	[t(7)	=	1.385,	p	=	0.211],	





















was	 no	 difference	 in	withdrawal	 scores	 before	 or	 after	morphine	
treatment;	mean	counts	of	head	shakes,	wet	dog	shakes,	teeth	chat-
tering,	 paw	 tremors,	 and	diarrhea	were	 all	 <1	 across	 both	30‐min	
sessions	(see	Table	1).






(i.e.,	 no	DA	antagonist)	 for	 the	early	phase	came	 from	 the	experi-
ment	establishing	morphine	dose	elicits	a	CPP	in	an	early	(6	mg/kg)	
TA B L E  1  Mean	counts	of	withdrawal	behaviors,	prior	to	and	following	morphine	treatment
Withdrawal measure
Pre‐morphine Post‐morphine
0–10 min 10–20 min 20–30 min 0–10 min 10–20 min 20–30 min
Head	shakes 0 0.13 0.13 0.38 0 0
Wet	dog	shakes 0 0 0 0 0 0.13
Teeth	chattering 0 0 0 0 0 0
Paw	tremors 0 0 0 0 0.25 0
Diarrhea 0 0 0 0 0 0
Mouthing 0.13 0 0.38 0 0.25 0












2.5.4 | Effects of DA antagonism on nociceptive  
responses
All	 CCI	 and	 sham	 animals	 underwent	 nociceptive	 testing	 for	 me-
























TA B L E  2  Subject	numbers	for	each	surgery	and	drug	group
Pain phase Surgery group Control
D1 antagonism D2 antagonism
SCH23390 Eticlopride
0.1 mg/kg 0.5 mg/kg 0.1 mg/kg 0.5 mg/kg
Early CCI n	=	8 n = 11 n = 12 n = 11 n = 10
Sham n	=	8 n = 10 n = 9 n = 9 n = 9
Late CCI n = 10 n = 11 n = 11 n = 10 n = 12
Sham n = 10 n	=	8 n = 9 n = 10 n = 9
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following	 conditioning	with	 SCH23390	 (0.5	mg/kg	 i.p.)	 and	 saline	
(1	ml/mg	s.c.),	using	the	protocol	described	previously	(i.e.,	no	mor-
phine	was	administered).	The	experiment	was	conducted	during	late	
phase	chronic	pain	 (i.e.,	 days	11–14	post‐surgery)	 to	coincide	with	
peak	nociceptive	responses	in	the	CCI	model.





of	chronic	pain	following	 injections	of	either	saline	 (1	ml/kg	 i.p)	or	
SCH233390	(0.5	mg/kg	i.p.)	administered	10	min	prior	to	morphine	
(6	or	2	mg/kg)	(n	=	6	each;	total	n	=	48).	Each	animal	was	tested	on	
the	 day	 prior	 to	 surgery	 (drug‐free)	 and	 then	 on	 four	 consecutive	
days	that	coincided	with	post‐surgery	days	and	times	of	CPP	con-
ditioning	sessions	 (i.e.,	days	4–7	and	11–14	 in	early	and	 late	phase	
chronic	pain).	Sensory	threshold	testing	was	initiated	10	min	follow-
ing	the	injection	of	morphine	and	was	completed	within	30	min.




Inc.,	Woodland	Hills,	 CA)	 that	 projects	 a	 beam	of	 light	 onto	 the	
rat's	 tail.	The	distal	5‐cm	portion	of	 the	 tail	was	blackened	with	
permanent	 marker	 to	 facilitate	 heat	 absorption.	 Heat	 intensity	
was	adjusted	to	elicit	tail	flick	latencies	between	2	and	3	s	with	a	
10‐s	cut	off	period.	The	tail	was	placed	under	the	heat	source	with	
the	 rat	gently	wrapped	 in	a	 towel;	 the	 time	to	 flick	 the	 tail	 from	
the	 heat	 source	 was	 recorded	 manually.	 The	 test	 was	 repeated	
10–15	min	 later	 and	 the	 average	 of	 the	 two	 latency	 scores	was	
used.
2.6 | Statistical analyses




(0,	 0.1,	 0.5	mg/kg),	 and	 side	 of	 CPP	 apparatus	 (drug‐paired,	 sa-
line‐paired)	were	 included	 as	 between‐subjects	 factors.	 A	 priori	
planned	orthogonal	comparisons	were	calculated	to	compare	the	
amount	 of	 time	 spent	 in	 drug‐	 and	 saline‐paired	 compartments	
during	 testing.	These	a	priori	 tests	are	used	 to	analyze	a	 limited	
number	of	predicted	hypotheses.	The	primary	advantage	of	con-
ducting	planned	orthogonal	 contrasts	 is	 that	 these	minimize	 the	
number	 of	 comparisons	 to	 those	 of	 interest,	 based	 on	 specific	
hypotheses	(e.g.,	CCI	rats	administered	 low‐dose	SCH	will	spend	
more	 time	 in	 the	morphine‐paired	compartment	 than	 the	saline‐















Using	 planned	 orthogonal	 comparison	 to	 analyze	 CPP	 data	
eliminates	 the	 possibility	 of	 comparing	 group	 differences	 in	 the	
magnitude	of	a	CPP.	To	deal	with	this	 issue,	we	created	the	vari-
able,	difference	score,	which	was	calculated	as	time	spent	in	mor-
phine‐paired	minus	 saline‐paired	 compartments	 for	 each	 group.	
These	difference	scores	were	compared	between	surgery	groups	
in	 the	 early	 and	 late	 phases	 of	 chronic	 pain	 experiments	 using	
independent	 samples	 t	 tests.	 In	 cases	 where	 assumptions	 were	
violated,	 we	 used	 a	 bootstrapped	 independent	 samples	 t test 
(number	 of	 samples	 =	 10,000),	 which	 is	 a	 non‐parametric	 alter-
native.	This	tests	samples	with	replacement	to	empirically	derive	
a	 null	 hypothesis	 distribution	 of	 the	 mean	 differences	 between	




using	 boxplots,	 the	 Shapiro–Wilk	 test,	 and	 Levene's	 test,	 respec-
tively.	Any	violations	are	presented	in	the	Results	section.	Outliers	
were	not	excluded	from	further	data	analysis.	Additionally,	we	have	




Data	 from	mechanical	 and	 thermal	 nociceptive	 tests	were	 an-
alyzed	 using	 separate	 mixed‐model	 repeated	 measures	 ANOVAs,	
which	 assess	 statistically	 significant	 differences	 between	 means	
of	 independent	groups.	 In	this	analysis,	surgery	(CCI	vs.	sham)	and	
drug	dose	were	 included	as	between‐subject	 factors	 and	day	was	
included	 as	 a	 within‐subjects	 (repeated)	 factor.	 Tukey's	 post	 hoc	
analysis	 was	 performed	 for	 multiple	 comparisons.	 Sphericity	 was	
assessed	using	Mauchly's	test	and	violations	were	corrected	using	a	







3.1 | Effects of DA antagonism on a morphine CPP
3.1.1 | Morphine CPP in early phase chronic pain
As	 shown	 in	 Figure	 2a	 and	 confirmed	 by	 a	 series	 of	 planned	
orthogonal	 comparisons,	 morphine	 (6	 mg/kg	 s.c.)	 produced	
a	 robust	CPP	 in	 both	 sham,	 t(104)	 =	 4.048,	p	 <	 0.001,	 and	CCI,	
t(104)	=	8.489,	p	<	0.001,	 rats	during	 the	early	phase	of	chronic	
pain.	The	magnitude	of	the	effect	was	 larger	 in	CCI	rats,	but	did	
not	 reach	 a	 statistical	 significance	 (bootstrapped	 independent	







0	 mg/kg,	 drug	 and	 saline‐paired	 sides;	 sham,	 0.1	 mg/kg,	 drug‐
paired	side).	Normality	was	violated	 in	one	group	 (CCI,	0	mg/kg,	
saline‐paired	 side),	 Shapiro–Wilk's	W	 =	0.737,	df	 =	8,	p = 0.006. 
The	 assumption	 of	 homogeneity	 of	 variance	 was	 also	 violated,	
p	 =	 0.039.	We	 used	 a	 bootstrapped	 independent	 samples	 t test 
to	compare	the	magnitude	of	morphine	CPP	in	CCI	and	sham	rats	
because	there	was	one	outlier	greater	 than	1.5	times	the	 IQR	 in	
the	CCI	group.
Eticlopride	 had	 no	 effect	 on	 a	morphine	 CPP	 in	 any	 of	 the	
groups	[sham	0.1	mg/kg:	t(98)	=	5.414,	p	<	0.001;	CCI	0.1	mg/kg:	
t(98)	=	7.338,	p	<	0.001;	sham	0.5	mg/kg	t(98)	=	3.801,	p < 0.001; 




















paired	 side).	Normality	was	violated	 in	 three	groups	 (sham,	0	mg/
kg,	 saline‐paired:	 Shapiro–Wilk	=	0.814,	df	 =	10,	p	 =	0.021;	 sham,	
0.1	mg/kg,	drug‐paired:	Shapiro–Wilk's	W	=	0.820,	df	=	8,	p	=	0.047;	
sham,	 0.5	 mg/kg,	 drug‐paired:	 Shapiro–Wilk's	 W	 =	 0.760,	 df	 =	 9,	
p	 =	 0.007).	 A	 bootstrapped	 independent	 samples	 t test was used 
to	compare	 the	magnitude	of	morphine	CPP	 in	CCI	and	sham	rats	






















3.2 | Effects of DA antagonism 
on nociceptive responses












(0.5	mg/kg;	p	=	0.008)	or	eticlopride	(0.1	and	0.5	mg/kg;	p = 0.001 
and p	<	0.001,	respectively),	compared	to	saline	controls.




pain.	 These	 effects	 were	 verified	 by	 a	 mixed‐model	 repeated	
measures	ANOVA,	which	 revealed	a	 significant	 surgery	×	 time	 in-
teraction	 in	 both	morphine	 plus	 SCH23390,	 F(20,	 212)	 =	 14.905,	











3.3 | Effects of DA D1 antagonism on place 
conditioning























p	<	0.001	(Figure	6a),	and	late,	F(12,	80)	=	9.721,	n	=	24,	p < 0.001 
(Figure	6c),	phases	of	chronic	pain,	with	similar	results	in	the	tail	flick	
test: F(12,	 80)	 =	7.416,	n	 =	24,	p < 0.001 and F(12,	 80)	 =	10.320,	
n	=	24,	p	<	0.001	(Figure	6b,d).	These	patterns	reflect	increased	no-
ciceptive	 responses	of	CCI	 compared	 to	 sham‐lesioned	 rats	 and	 a	
decline	in	the	effectiveness	of	morphine	across	sessions	(i.e.,	toler-
ance).	 Tukey's	 post	 hoc	 tests	 confirmed	 no	 significant	 differences	











parallel	 evidence	 that	DA	D1	antagonism	 reduces	morphine	 reward	
in	opiate‐naïve,	 but	not	opiate‐dependent,	 rats	 (Lintas	 et	 al.,	 2011).	
In	contrast,	D2	receptor	blockade	did	not	disrupt	a	morphine	CPP	in	




to	establish	morphine	dependence	 in	other	CPP	 studies	 (Laviolette,	


















CPP	 in	CCI	 rats	 strengthens	 the	 contention	 that	 neuropathic	pain	
alters	DAergic	mechanisms	of	 opiate	 reward	 (Asaoka	 et	 al.,	 2018;	




DA	 release	 within	 the	 NAc,	 which	 is	 positively	 correlated	 with	 a	
decrease	 in	VTA	dopaminergic	cell	 firing	 (Ren,	Centeno,	&	Berger,	
2016).	 Importantly,	 this	 latter	 study	 suggested	 that	DA	hypofunc-
tion	was	at	 least	partially	responsible	for	pain	hypersensitivities	 in	
neuropathic	 pain	 as	 treatment	with	 levodopa	 attenuated	mechan-
ical	 tactile	 allodynia.	 Additionally,	 optogenetic	 activation	 of	 DA	
neurons	attenuated	thermal	hyperalgesia	in	a	model	of	neuropathic	























Poe,	 &	 Campos‐Jurado,	 2015).	 On	 the	 other	 hand,	 the	 rewarding	
effect	of	morphine	is	reduced	in	intracranial	self‐stimulation	(Ewan	






Bechara	 &	 Kooy,	 1992)	 to	 dissociate	 these	 two	 effects,	 revealing	
that	 the	negative	affective	states	associated	with	chronic	pain	are	
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antagonist	 reduced	 final	day	pain	 scores	 in	both	experiments,	 but	
this	manipulation	 had	 no	 effect	 on	 a	morphine	CPP.	More	 impor-
tantly,	 subsequent	 testing	 confirmed	 that	 our	 drug	 regime	 which	
reduced	a	morphine	CPP	(i.e.,	high	dose	SCH	23390)	did	not	impact	




antagonists	 altering	 morphine‐induced	 analgesia	 in	 chronic	 pain,	
although	 these	 drugs	may	 attenuate	 the	 antinociceptive	 effect	 of	




changes	 in	DA	responses	 to	 rewarding	stimuli	continue	 to	evolve	up	
to	30	days	following	nerve	ligation	(Kato	et	al.,	2016).	We	selected	a	
shorter	 time	window	 for	 behavioral	 assessment	 because	nociceptive	






















pharmaceutical	 therapies	 show	 limited	 efficacy	 and	 large	 placebo	
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